J B Chemicals & Pharmaceuticals
J B Chemicals & Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for J B Chemicals & Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
J B Chemicals & Pharmaceuticals Ltd trades at a P/E of 50.87× and P/B of 8.72×.
Valuation
Profitability
Growth
Financial Health
J B Chemicals & Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for J B Chemicals & Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
J B Chemicals & Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹36,254.16 Cr and reported EPS of ₹44.38.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,414 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,918 | 4,148 |
| Other Income | 37 | 41 | 51 | 112 | 39 | 10 | 37 | 38 | 60 |
| Total Income | 1,450 | 1,685 | 1,825 | 2,155 | 2,463 | 3,159 | 3,521 | 3,956 | 4,208 |
| Cost of Goods Sold (COGS) | 538 | 596 | 631 | 701 | 843 | 1,168 | 1,182 | 1,317 | 1,296 |
| Gross Profit | 876 | 1,047 | 1,144 | 1,341 | 1,581 | 1,981 | 2,302 | 2,601 | 2,852 |
| +Operating Expenses | 658 | 741 | 766 | 781 | 1,038 | 1,285 | 1,405 | 1,570 | 1,744 |
| EBITDA | 218 | 305 | 378 | 560 | 543 | 696 | 897 | 1,032 | 1,107 |
| +Non-Operating Expenses | 60 | 60 | 59 | 76 | 78 | 150 | 183 | 183 | 161 |
| Profit Before Tax (PBT) | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 952 |
| +Tax Expense | 55 | 93 | 77 | 148 | 119 | 145 | 199 | 228 | 243 |
| Profit After Tax (PAT) | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 709 |
| Earnings Per Share (EPS) | 8.25 | 12.09 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 42.37 | 44.19 |
| Diluted Shares Outstanding (Nos.) | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
| +Additional Disclosures | 1,794 | 1,990 | 2,083 | 2,260 | 2,806 | 3,759 | 3,937 | 4,394 | 4,551 |
| Sales Growth % | — | 16.25 | 8.00 | 15.09 | 18.69 | 29.91 | 10.63 | 12.45 | 5.87 |
| YoY Sales Growth % | — | 16.25 | 8.00 | 15.09 | 18.69 | 29.91 | 10.63 | 12.45 | 5.87 |
| Material Cost % | 27 | 28 | 25 | 27 | 25 | 25 | 23 | 21 | 22 |
| Employee Cost % | 18 | 18 | 18 | 17 | 18 | 17 | 17 | 18 | 19 |
| Other Cost % | 29 | 28 | 25 | 22 | 25 | 24 | 23 | 23 | 23 |
| OPM % | 15 | 19 | 21 | 27 | 22 | 22 | 26 | 26 | 27 |
| Tax % | 28 | 32 | 22 | 25 | 24 | 26 | 26 | 26 | 26 |
| Profit Growth % | — | 39.83 | 40.43 | 64.66 | -13.93 | 6.21 | 34.79 | 19.35 | 7.56 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 161 | 250 | 311 | 492 | 471 | 581 | 759 | 861 | 925 |
J B Chemicals & Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at J B Chemicals & Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
J B Chemicals & Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
J B Chemicals & Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy J B Chemicals & Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
J B Chemicals & Pharmaceuticals Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
J B Chemicals shows robust profitability with a 20.10% ROE and 26.30% OPM, indicating efficient operations and strong shareholder returns. A healthy 25.80% ROCE further supports its financial strength and effective capital utilization.
The company exhibits consistent growth, reporting a significant 14.40% increase in quarterly profits. This positive trend indicates a healthy and expanding business model, capable of delivering sustained profitability and value creation for investors in the long term.
J B Chemicals maintains a very strong financial position with an exceptionally low debt-to-equity ratio of 0.01. This minimal leverage significantly reduces financial risk and provides substantial flexibility for future strategic investments and expansion initiatives.
The company's current PE ratio of 38.90, while higher than some peers, is considered reasonable given its strong growth trajectory and solid financial performance, suggesting potential for continued appreciation as earnings expand.
The robust growth in the global pharmaceutical market, driven by increasing healthcare expenditure and an aging population, presents significant opportunities for J B Chemicals to expand its market share and product offerings.
What can break it.
Promoter holdings have seen a notable decrease from 54.00% in June 2022 to 47.56% by September 2025. This significant reduction raises concerns about potential future share dilution and could signal decreased management confidence or control.
Despite overall profit growth, the stock has shown recent volatility, with a five-day decline of -0.69%. This short-term negative movement indicates some market uncertainty and could impact investor sentiment, warranting close monitoring.
While the debt-to-equity ratio is low, the absolute debt of 27.9 (units unspecified) could still pose a risk if growth decelerates or interest rates rise. Clarity on the nature and scale of this debt is crucial for a complete risk assessment.
The company's PE ratio of 38.90 is higher than several key industry peers like Cipla (23.65) and Dr Reddy's (18.09), suggesting that the market is pricing in substantial future growth, which carries a risk if these expectations are not met.
Intense competition from both domestic and international pharmaceutical giants poses a significant threat, potentially leading to pricing pressures and challenges in maintaining market share and profitability for J B Chemicals.
What would change my mind.
Trim if P/E re-rates above 66. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 14%. The operating engine is no longer compounding capital efficiently.
J B Chemicals & Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — J B Chemicals & Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
J B Chemicals & Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for J B Chemicals & Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
J B Chemicals & Pharmaceuticals Ltd last traded at ₹2,257.7 with an intraday range of ₹2,252.1–₹2,300 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2257.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2383.57 | +125.87 | +5.57% |
| R3 | 2335.67 | +77.97 | +3.45% |
| R2 | 2317.83 | +60.13 | +2.66% |
| R1 | 2287.77 | +30.07 | +1.33% |
| PIVOT | 2269.93 | 12.23 | 0.54% |
| CURRENT | 2257.70 | — | — |
| S1 | 2144.07 | -113.63 | -5.03% |
| S2 | 2191.97 | -65.73 | -2.91% |
| S3 | 2222.03 | -35.67 | -1.58% |
| S4 | 2239.87 | -17.83 | -0.79% |
JBCHEPHARM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 2257.9 ~ 2280
Trading Inside opening range
J B Chemicals & Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for J B Chemicals & Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in J B Chemicals & Pharmaceuticals Ltd stood at 52.3% of traded volume, against a 20-day average of 57.1%.
J B Chemicals & Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings J B Chemicals & Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
J B Chemicals & Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 149 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Newspaper advertisement pertaining to financial results for the quarter and…
Shareholders meeting
JB Chemicals & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Court Convened General Meeting held on April 28,…
Shareholders meeting
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about proceedings of the NCLT convened meeting
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
J B Chemicals & Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in J B Chemicals & Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
J B Chemicals & Pharmaceuticals insider activity below tracks 33 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr | ₹2,110.00 |
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr | ₹2,110.00 |
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr | ₹2,110.00 |
| Parmeshwar Bang | Insider | 12 Jun 2025 | buy | +1.1 K | ₹19.28 L | ₹1,752.73 |
| Vikas Khare | Insider | 12 Jun 2025 | sell | −950 | ₹16.66 L | ₹1,753.34 |
| Sandeep Phadnis | Insider | 12 Jun 2025 | sell | −1.0 K | ₹17.56 L | ₹1,755.62 |
| Parmeshwar Bang | Insider | 12 Jun 2025 | sell | −1.1 K | ₹19.28 L | ₹1,752.73 |
| Nikhil Ashokkumar Chopra | Insider | 11 Jun 2025 | buy | +50.0 K | ₹8.8 Cr | ₹1,760.00 |
| Kunal Khanna | Insider | 11 Jun 2025 | buy | +21.1 K | ₹3.59 Cr | ₹1,706.32 |
| Narayan Prasad Saraf | Insider | 11 Jun 2025 | buy | +21.5 K | ₹3.79 Cr | ₹1,760.00 |
J B Chemicals & Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue J B Chemicals & Pharmaceuticals has declared, sequenced by announce and record date.
J B Chemicals & Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About J B Chemicals & Pharmaceuticals Ltd: business, sector, key facts.
What J B Chemicals & Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
J B Chemicals & Pharmaceuticals Ltd operates in the Healthcare, listed as NSE: JBCHEPHARM, BSE: 506943.
J.B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) is a prominent Indian pharmaceutical company engaged in the manufacture and marketing of a diverse range of pharmaceutical products both domestically and internationally. Their business model encompasses three core areas: pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs).
A significant portion of JBCHEPHARM's business revolves around the production and sale of APIs, which are the fundamental building blocks of many pharmaceutical drugs. Their API portfolio is extensive and includes key ingredients for various therapeutic applications, such as diclofenac sodium, nifedipine, atenolol, ciprofloxacin, and cetirizine, amongst others. This allows them to control a key stage in the supply chain and provide components to other pharmaceutical companies, as well as use them internally.
Beyond APIs, JBCHEPHARM manufactures and markets a wide array of finished pharmaceutical formulations. These encompass various dosage forms designed to cater to a broad spectrum of therapeutic needs, including tablets, capsules, injectables, gels, creams, ointments, syrups, and lozenges. The company's product portfolio covers a comprehensive range of therapeutic areas, encompassing gastroenterology, anti-infectives, wound care, pediatrics, gynecology, dentistry, vitamins and minerals, hypertension, diabetes, nephrology, respiratory ailments, pain management, dermatology, antivirals, and contrast media for medical imaging.
In addition to their core pharmaceutical business, JBCHEPHARM also offers herbal remedies, expanding their product offerings to encompass traditional medicine. This diversification further strengthens their market position and caters to a broader consumer base. Furthermore, the company provides contract manufacturing services, leveraging its manufacturing capabilities to produce products for other companies in the pharmaceutical industry.
JBCHEPHARM's integrated approach, encompassing API manufacturing, formulation development, and contract manufacturing, positions it as a significant player within the Indian and international pharmaceutical markets. Their broad therapeutic coverage and diversified product portfolio contribute to their market success. The company’s long history, established in 1976, speaks to their resilience and adaptability within a constantly evolving industry.
Questions investors ask about J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM)?
The current share price of J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is ₹2,257.7. Today, the stock has gained by ₹5.00 (0.22%), trading in a range of ₹2,252.1 to ₹2,300. The stock opened at ₹2,276.5 with a trading volume of 2,35,603 shares.
02Is J B Chemicals & Pharmaceuticals Ltd stock a good investment for long-term?
J B Chemicals & Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹36,254.16 crores, P/E ratio of 50.87, ROE of 18.69%, and ROCE of 25.80%. The dividend yield stands at 0.83%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of J B Chemicals & Pharmaceuticals Ltd stock?
The 52-week high price of J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is ₹0, while the 52-week low is ₹0. Currently trading at ₹2,257.7, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy J B Chemicals & Pharmaceuticals Ltd stock at the current price?
Whether to buy J B Chemicals & Pharmaceuticals Ltd stock at ₹2,257.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.87 and P/B ratio of 8.72. Today's performance shows a gain of 0.22%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of J B Chemicals & Pharmaceuticals Ltd and when is the next dividend?
J B Chemicals & Pharmaceuticals Ltd offers a dividend yield of 0.83%, which means for every ₹100 invested at the current price of ₹2,257.7, you can expect to receive approximately ₹0.83 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of J B Chemicals & Pharmaceuticals Ltd?
J B Chemicals & Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 50.87, P/B Ratio: 8.72, ROE: 18.69%, ROCE: 25.80%, Dividend Yield: 0.83%, EPS: ₹44.38, Book Value: ₹259.05, and Debt-to-Equity: 0.09. The company's market cap stands at ₹36,254.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is J B Chemicals & Pharmaceuticals Ltd stock performing today in the market?
J B Chemicals & Pharmaceuticals Ltd stock opened at ₹2,276.5 and is currently trading at ₹2,257.7, showing a gain of ₹5.00 (0.22%). The intraday high is ₹2,300 and low is ₹2,252.1. The trading volume stands at 2,35,603 shares, indicating moderate market participation today.
08What is the P/E ratio of J B Chemicals & Pharmaceuticals Ltd and what does it indicate?
J B Chemicals & Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 50.87, which means investors are willing to pay ₹50.87 for every ₹1 of earnings. With an EPS of ₹44.38, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy